vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Powerfleet, Inc. (AIOT). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $113.5M, roughly 1.2× Powerfleet, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -3.0%, a 38.4% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 6.6%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $4.9M). Over the past eight quarters, Powerfleet, Inc.'s revenue compounded faster (81.2% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Powerfleet, Inc. is an American company headquartered in Woodcliff Lake, New Jersey, that operates as a global provider of IoT and M2M solutions for securing, controlling, and tracking high-value enterprise assets. The company is a provider in the international telematics industry, providing fleet management, asset tracking, freight visibility, and driver behavior monitoring for industrial trucks, vehicle fleets, and shipping containers.
ADMA vs AIOT — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $113.5M |
| Net Profit | $49.4M | $-3.4M |
| Gross Margin | 63.8% | 55.2% |
| Operating Margin | 45.1% | 5.6% |
| Net Margin | 35.5% | -3.0% |
| Revenue YoY | 18.4% | 6.6% |
| Net Profit YoY | -55.9% | 76.6% |
| EPS (diluted) | $0.20 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $113.5M | ||
| Q3 25 | $134.2M | $111.7M | ||
| Q2 25 | $122.0M | $104.1M | ||
| Q1 25 | $114.8M | $103.6M | ||
| Q4 24 | $117.5M | $106.4M | ||
| Q3 24 | $119.8M | $77.0M | ||
| Q2 24 | $107.2M | $75.4M | ||
| Q1 24 | $81.9M | — |
| Q4 25 | $49.4M | $-3.4M | ||
| Q3 25 | $36.4M | $-4.3M | ||
| Q2 25 | $34.2M | $-10.2M | ||
| Q1 25 | $26.9M | $-12.4M | ||
| Q4 24 | $111.9M | $-14.3M | ||
| Q3 24 | $35.9M | $-1.9M | ||
| Q2 24 | $32.1M | $-22.3M | ||
| Q1 24 | $17.8M | — |
| Q4 25 | 63.8% | 55.2% | ||
| Q3 25 | 56.3% | 56.0% | ||
| Q2 25 | 55.1% | 54.2% | ||
| Q1 25 | 53.2% | 52.8% | ||
| Q4 24 | 53.9% | 55.2% | ||
| Q3 24 | 49.8% | 53.7% | ||
| Q2 24 | 53.6% | 52.6% | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 5.6% | ||
| Q3 25 | 38.0% | 3.8% | ||
| Q2 25 | 35.1% | -2.0% | ||
| Q1 25 | 30.4% | -6.7% | ||
| Q4 24 | 32.6% | -1.2% | ||
| Q3 24 | 33.1% | 0.7% | ||
| Q2 24 | 36.6% | -24.2% | ||
| Q1 24 | 26.7% | — |
| Q4 25 | 35.5% | -3.0% | ||
| Q3 25 | 27.1% | -3.8% | ||
| Q2 25 | 28.1% | -9.8% | ||
| Q1 25 | 23.4% | -12.0% | ||
| Q4 24 | 95.2% | -13.5% | ||
| Q3 24 | 30.0% | -2.5% | ||
| Q2 24 | 29.9% | -29.6% | ||
| Q1 24 | 21.7% | — |
| Q4 25 | $0.20 | $-0.03 | ||
| Q3 25 | $0.15 | $-0.03 | ||
| Q2 25 | $0.14 | $-0.08 | ||
| Q1 25 | $0.11 | $-0.09 | ||
| Q4 24 | $0.45 | $-0.11 | ||
| Q3 24 | $0.15 | $-0.02 | ||
| Q2 24 | $0.13 | $-0.21 | ||
| Q1 24 | $0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $31.2M |
| Total DebtLower is stronger | $72.1M | $237.8M |
| Stockholders' EquityBook value | $477.3M | $485.0M |
| Total Assets | $624.2M | $959.5M |
| Debt / EquityLower = less leverage | 0.15× | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $31.2M | ||
| Q3 25 | $61.4M | $27.9M | ||
| Q2 25 | $90.3M | $31.2M | ||
| Q1 25 | $71.6M | $44.4M | ||
| Q4 24 | $103.1M | $33.6M | ||
| Q3 24 | $86.7M | $26.0M | ||
| Q2 24 | $88.2M | $30.2M | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | $237.8M | ||
| Q3 25 | $72.4M | $238.2M | ||
| Q2 25 | — | $239.0M | ||
| Q1 25 | — | $237.5M | ||
| Q4 24 | $72.3M | $238.5M | ||
| Q3 24 | — | $113.6M | ||
| Q2 24 | — | $113.7M | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $485.0M | ||
| Q3 25 | $431.2M | $468.8M | ||
| Q2 25 | $398.3M | $460.7M | ||
| Q1 25 | $373.4M | $446.6M | ||
| Q4 24 | $349.0M | $458.4M | ||
| Q3 24 | $231.9M | $451.0M | ||
| Q2 24 | $188.3M | $390.4M | ||
| Q1 24 | $153.7M | — |
| Q4 25 | $624.2M | $959.5M | ||
| Q3 25 | $568.7M | $936.9M | ||
| Q2 25 | $558.4M | $930.8M | ||
| Q1 25 | $510.6M | $910.1M | ||
| Q4 24 | $488.7M | $908.7M | ||
| Q3 24 | $390.6M | $748.3M | ||
| Q2 24 | $376.4M | $684.9M | ||
| Q1 24 | $350.9M | — |
| Q4 25 | 0.15× | 0.49× | ||
| Q3 25 | 0.17× | 0.51× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | 0.21× | 0.52× | ||
| Q3 24 | — | 0.25× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $10.2M |
| Free Cash FlowOCF − Capex | $34.6M | $4.9M |
| FCF MarginFCF / Revenue | 24.8% | 4.4% |
| Capex IntensityCapex / Revenue | 0.8% | 4.6% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $12.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $10.2M | ||
| Q3 25 | $13.3M | $5.5M | ||
| Q2 25 | $21.1M | $4.7M | ||
| Q1 25 | $-19.7M | $13.5M | ||
| Q4 24 | $50.2M | $-6.1M | ||
| Q3 24 | $25.0M | $-3.2M | ||
| Q2 24 | $45.6M | $-7.6M | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | $34.6M | $4.9M | ||
| Q3 25 | $-1.1M | $1.2M | ||
| Q2 25 | $18.7M | $-3.4M | ||
| Q1 25 | $-24.4M | $10.1M | ||
| Q4 24 | $47.5M | $-12.2M | ||
| Q3 24 | $24.0M | $-8.0M | ||
| Q2 24 | $43.6M | $-13.2M | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | 4.4% | ||
| Q3 25 | -0.8% | 1.1% | ||
| Q2 25 | 15.3% | -3.3% | ||
| Q1 25 | -21.2% | 9.8% | ||
| Q4 24 | 40.4% | -11.5% | ||
| Q3 24 | 20.0% | -10.4% | ||
| Q2 24 | 40.7% | -17.5% | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | 4.6% | ||
| Q3 25 | 10.7% | 3.9% | ||
| Q2 25 | 2.0% | 7.8% | ||
| Q1 25 | 4.1% | 3.3% | ||
| Q4 24 | 2.3% | 5.8% | ||
| Q3 24 | 0.9% | 6.3% | ||
| Q2 24 | 1.9% | 7.4% | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
AIOT
| Services | $91.1M | 80% |
| Products | $22.4M | 20% |
